A group of lawmakers has asked the U.S. Food and Drug Administration to reconsider a proposed rule regarding drug labeling, saying it was designed to shield pharmaceutical and device companies from liability for injuries sustained by American consumers as a result of unsafe products.
Plaintiffs in multidistrict litigation over AstraZeneca LP's blockbuster Seroquel have asked a court for permission to depose doctors who conducted clinical trials and wrote papers supporting the controversial anti-psychotic drug.
The dispute between law firm Sullivan & Cromwell LLP and e-discovery firm Electronic Evidence Discovery Inc. may have been settled out of court, but the suit highlights the struggle between attorneys and legal services companies that continues to play out at firms across the country.
A judge has granted biopharmaceutical company Oculus Innovative Sciences Inc. $6.6 million in damages, finding that the company suffered a loss after Japanese machine manufacturer Nofil Corp. breached nondisclosure and exclusive purchase agreements relating to Oculus’ intellectual property for its Microcyn disinfectant.
Merck & Co. and Schering-Plough Corp. continued to defend a controversial study of their Vytorin and Zetia cholesterol treatments Friday on the heels of the U.S. Food and Drug Administration announcing that it will review the study once it receives the final results.
A Democratic lawmaker has once again demanded that the Food and Drug Administration turn over information about a draft proposal that would give drug companies free rein to use journal articles to promote unapproved medication uses.
Stryker Corp. is pulling certain hip implant components manufactured under its popular Trident line just days after the U.S. Food and Drug Administration warned the company it could face regulatory action if it fails to address quality control issues with its joint replacement devices.
A new study is warning about the potential side effects of Nexavar, maintaining that the drug used to treat kidney and liver cancer can trigger a significant spike in blood pressure.
A federal judge overseeing the multidistrict litigation over the cholesterol-lowering drug Baycol has given more than 400 plaintiffs two weeks to show cause why their claims should not be dismissed from the massive case.
Personal Touch Home Care Inc. is facing a putative collective action accusing the company of implementing a companywide scheme to deny its office personnel minimum wage and overtime compensation by not paying prospective class members for all the hours they worked.
Citing an earlier Vioxx case ruling, a federal judge has rejected the bid of health care products maker C.R. Bard Inc. to speak off the record with the plaintiffs' doctors in the multidistrict product liability case over a purportedly defective hernia mesh patch.
North Carolina manufacturer AM2 Pat Inc. has recalled all lots and sizes of its syringes prefilled with Heparin or saline, after discovering that they may be contaminated with the bacteria Serratia marcescens.
Members of the New York state Congress urged the Bush administration on Thursday to rethink axing a Sept. 11, 2001, health program that would have helped sick respondents who live outside the tristate area.
Pharmaceutical giant Johnson & Johnson is fighting efforts to consolidate the bellwether trials in the multidistrict litigation over its popular birth control patch, Ortho-Evra, arguing commonalities in the cases are eclipsed by their idiosyncrasies.
Generics drugmaker Barr Pharmaceuticals Inc. announced Tuesday it was in negotiations with a Johnson & Johnson unit to resolve a four-year patent dispute over blockbuster oral contraceptive pill Ortho Tri-Cyclen.
Merck & Co. and Schering-Plough Corp. are yanking television ads for Vytorin amid proposed class actions and a congressional inquiry on the effectiveness of the cholesterol drug.
Medical technology company Diomed Holdings Inc. said Tuesday that rival Total Vein Solutions filed for Chapter 11 bankruptcy protection just before a hearing in a long-running patent dispute between the two firms.
While the European Commission appears to have taken a cue from the U.S. Federal Trade Commission in cracking down on potential antitrust issues and patent abuse in the pharmaceutical industry, the EC's inquiry began in a unique fashion: with unannounced dawn raids typically reserved for cartels. The approach of the EC is likely to differ from that of the U.S. in other ways, too, attorneys say.
Ranbaxy Laboratories Ltd. said it has reached a settlement with GlaxoSmithKline Plc, putting a stop to any possible patent litigation over a generic version of GSK's migraine drug Imitrex.
The federal judge overseeing the Prempro suit has set the trial timetable, awarding the plaintiff 50% of the total time and each of the defendants 25% to present their respective cases on whether the controversial hormone replacement drug causes breast cancer.